Methylprednisolone ( DrugBank: Methylprednisolone )


46 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
11Myasthenia gravis3
13Multiple sclerosis/Neuromyelitis optica58
14Chronic inflammatory demyelinating polyneuropathy2
18Spinocerebellar degeneration1
19Lysosomal storage disease2
25Progressive multifocal leukoencephalopathy2
26HTLV-1-associated myelopathy2
35Pemphigus1
38Stevens-Johnson syndrome1
39Toxic epidermal necrolysis1
40Takayasu arteritis1
41Giant cell arteritis1
42Polyarteritis nodosa2
43Microscopic polyangiitis4
45Eosinophilic granulomatosis with Polyangiitis2
46Malignant rheumatoid arthritis37
49Systemic lupus erythematosus17
50Dermatomyositis12
51Scleroderma10
60Aplastic anemia13
62Paroxysmal nocturnal hemoglobinuria1
63Idiopathic thrombocytopenic purpura2
64Thrombotic thrombocytopenic purpura1
65Primary immunodeficiency5
66IgA nephropathy11
83Addison disease1
84Sarcoidosis1
85Idiopathic interstitial pneumonia1
86Pulmonary arterial hypertension1
93Primary biliary cholangitis2
95Autoimmune hepatitis1
96Crohn disease4
97Ulcerative colitis6
145West syndrome1
162Pemphigoid3
164Oculocutaneous albinism1
211Hypoplastic left heart syndrome1
220Rapidly progressive glomerulonephritis1
222Primary nephrotic syndrome9
224Purpura nephritis1
271Ankylosing spondylitis1
283Acquired pure red cell aplasia1
284Diamond-Blackfan anemia2
285Fanconi anemia7
296Biliary atresia1

2. Amyotrophic lateral sclerosis


Clinical trials : 645Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

11. Myasthenia gravis


Clinical trials : 332Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 175Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

18. Spinocerebellar degeneration


Clinical trials : 76Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

19. Lysosomal storage disease


Clinical trials : 899Drugs : 684 - (DrugBank : 99) / Drug target genes : 51 - Drug target pathways : 182 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

25. Progressive multifocal leukoencephalopathy


Clinical trials : 26Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

26. HTLV-1-associated myelopathy


Clinical trials : 29Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

35. Pemphigus


Clinical trials : 99Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

38. Stevens-Johnson syndrome


Clinical trials : 17Drugs : 29 - (DrugBank : 9) / Drug target genes : 15 - Drug target pathways : 101 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

39. Toxic epidermal necrolysis


Clinical trials : 13Drugs : 19 - (DrugBank : 8) / Drug target genes : 11 - Drug target pathways : 103 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

40. Takayasu arteritis


Clinical trials : 24Drugs : 40 - (DrugBank : 18) / Drug target genes : 23 - Drug target pathways : 110 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

41. Giant cell arteritis


Clinical trials : 131Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

42. Polyarteritis nodosa


Clinical trials : 15Drugs : 26 - (DrugBank : 16) / Drug target genes : 26 - Drug target pathways : 105 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

43. Microscopic polyangiitis


Clinical trials : 88Drugs : 81 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 90 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

45. Eosinophilic granulomatosis with Polyangiitis


Clinical trials : 31Drugs : 44 - (DrugBank : 18) / Drug target genes : 18 - Drug target pathways : 101 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,356Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 993Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

50. Dermatomyositis


Clinical trials : 194Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

60. Aplastic anemia


Clinical trials : 245Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 292Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 391Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

64. Thrombotic thrombocytopenic purpura


Clinical trials : 92Drugs : 85 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 76 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 500Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 275Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

83. Addison disease


Clinical trials : 20Drugs : 39 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 18 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 149Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 627Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

86. Pulmonary arterial hypertension


Clinical trials : 1,205Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

93. Primary biliary cholangitis


Clinical trials : 298Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

95. Autoimmune hepatitis


Clinical trials : 52Drugs : 68 - (DrugBank : 27) / Drug target genes : 18 - Drug target pathways : 111 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,442Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 2,630Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

145. West syndrome


Clinical trials : 43Drugs : 52 - (DrugBank : 15) / Drug target genes : 28 - Drug target pathways : 26 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

162. Pemphigoid


Clinical trials : 90Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

164. Oculocutaneous albinism


Clinical trials : 15Drugs : 54 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 141 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

211. Hypoplastic left heart syndrome


Clinical trials : 22Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

220. Rapidly progressive glomerulonephritis


Clinical trials : 2Drugs : 4 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathway : 1 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 310Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

224. Purpura nephritis


Clinical trials : 16Drugs : 43 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 58 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

271. Ankylosing spondylitis


Clinical trials : 574Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

283. Acquired pure red cell aplasia


Clinical trials : 19Drugs : 36 - (DrugBank : 23) / Drug target genes : 20 - Drug target pathways : 102 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

284. Diamond-Blackfan anemia


Clinical trials : 36Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

285. Fanconi anemia


Clinical trials : 62Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

296. Biliary atresia


Clinical trials : 71Drugs : 70 - (DrugBank : 39) / Drug target genes : 35 - Drug target pathways : 60 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries